TY  - JOUR
AU  - Brown, Emmeline E
AU  - Blauwendraat, Cornelis
AU  - Trinh, Joanne
AU  - Rizig, Mie
AU  - Nalls, Mike A
AU  - Leveille, Etienne
AU  - Ruskey, Jennifer A
AU  - Jonvik, Hallgeir
AU  - Tan, Manuela M X
AU  - Bandres-Ciga, Sara
AU  - Hassin-Baer, Sharon
AU  - Brockmann, Kathrin
AU  - Infante, Jon
AU  - Tolosa, Eduardo
AU  - Ezquerra, Mario
AU  - Ben Romdhan, Sawssan
AU  - Benmahdjoub, Mustapha
AU  - Arezki, Mohamed
AU  - Mhiri, Chokri
AU  - Hardy, John
AU  - Singleton, Andrew B
AU  - Alcalay, Roy N
AU  - Gasser, Thomas
AU  - Grosset, Donald G
AU  - Williams, Nigel M
AU  - Pittman, Alan
AU  - Gan-Or, Ziv
AU  - Fernandez-Santiago, Ruben
AU  - Brice, Alexis
AU  - Lesage, Suzanne
AU  - Farrer, Matthew
AU  - Wood, Nicholas
AU  - Morris, Huw R
PY  - 2020
DO  - 10.1016/j.neurobiolaging.2020.07.002
UR  - http://hdl.handle.net/10668/16190
T2  - Neurobiology of aging
AB  - The LRRK2 gene has rare (p.G2019S) and common risk variants for Parkinson's disease (PD). DNM3 has previously been reported as a genetic modifier of the age at onset in PD patients carrying the LRRK2 p.G2019S mutation. We analyzed this effect in a new...
LA  - en
PB  - Elsevier Inc.
KW  - Genetic modifiers
KW  - Leucine-rich repeat kinase 2
KW  - Parkinsonism
KW  - Parkinson’s disease
KW  - Age of Onset
KW  - Aged
KW  - Cohort Studies
KW  - Dynamin III
KW  - Epistasis, Genetic
KW  - Female
KW  - Genetic Association Studies
KW  - Genetic Predisposition to Disease
KW  - Genetic Variation
KW  - Humans
KW  - Leucine-Rich Repeat Serine-Threonine Protein Kinase-2
KW  - Linkage Disequilibrium
KW  - Male
KW  - Middle Aged
KW  - Parkinson Disease
KW  - R-SNARE Proteins
KW  - Risk
TI  - Analysis of DNM3 and VAMP4 as genetic modifiers of LRRK2 Parkinson's disease.
TY  - research article
VL  - 97
ER  -